
Détail de l'auteur
Auteur F. MARCELLIN |
Documents disponibles écrits par cet auteur (8)

![]()
Article : Périodique
B. ROLLAND ; C. LIONS ; V. DI BEO ; P. CARRIERI ; N. AUTHIER ; T. BARRE ; J. DELORME ; P. MATHURIN ; F. BAILLY ; C. PROTOPOPESCU ; F. MARCELLIN |Background: Opioid agonist therapy (OAT) is associated with reduced injection, reduced HCV transmission, and more opportunities to initiate hepatitis C virus (HCV) treatment in people who use drugs (PWUD). We aimed to study the extent to which a[...]![]()
Article : Périodique
P. ROUX ; B. DEMOULIN ; P. SOGNI ; P. CARRIERI ; R. DRAY-SPIRA ; B. SPIRE ; F. MARCELLIN ; Groupe Vespa2 |FRANÇAIS : L'infection par le virus de l'hépatite C (VHC) chez les personnes vivant avec le VIH (PVVIH) demeure un problème majeur de santé publique et pose des difficultés de prise en charge combinée de ces deux infections. L'enquête Vespa2 (V[...]![]()
Article : Périodique
M. E. SANTOS ; C. PROTOPOPESCU ; P. SOGNI ; I. YAYA ; L. PIROTH ; F. BAILLY ; F. MARCELLIN ; L. ESTERLE ; L. WITTKOP ; E. ROSENTHAL ; P. MORLAT ; P. ROUX ; W. N. DE ARAUJO ; D. SALMON-CERON ; M. P. CARRIERI ; ANRS CO13-HEPAVIH Study Group |Mortality among individuals co-infected with HIV and hepatitis C virus (HCV) is relatively high. We evaluated the association between psychoactive substance use and both HCV and non-HCV mortality in HIV/HCV co-infected patients in France, using [...]![]()
Article : Périodique
T. ROJAS ROJAS ; V. DI BEO ; J. DELORME ; T. BARRE ; P. MATHURIN ; C. PROTOPOPESCU ; F. BAILLY ; M. COSTE ; N. AUTHIER ; M. P. CARRIERI ; B. ROLLAND ; F. MARCELLIN |Background: In the era of direct-acting antivirals (DAA) for the treatment of hepatitis C virus (HCV) infection, HCV treatment uptake remains insufficiently documented in key populations such as people with opioid dependence. Access to opioid ag[...]![]()
Article : Périodique
M. P. CARRIERI ; L. MICHEL ; C. LIONS ; J. COHEN ; M. VRAY ; M. MORA ; F. MARCELLIN ; B. SPIRE ; A. MOREL ; P. ROUX ; The Methaville Study Group |Objective: Methadone coverage is poor in many countries due in part to methadone induction being possible only in specialized care (SC). This multicenter pragmatic trial compared the effectiveness of methadone treatment between two induction mod[...]![]()
Article : Périodique
T. BARRE ; C. RAMIER ; S. ANTWERPES ; M. COSTA ; M. BUREAU ; G. MARADAN ; V. DI BEO ; C. CUTARELLA ; J. LELOUTRE ; O. RICCOBONO-SOULIER ; S. HEDOIRE ; E. FROT ; F. VERNIER ; S. VASSAS-GOYARD ; S. DUFORT ; C. PROTOPOPESCU ; F. MARCELLIN ; D. CASANOVA ; M. COSTE ; P. CARRIERI |INTRODUCTION: Alcohol use disorder (AUD) is associated with a significant disease burden in France, where alcohol use is deeply rooted in culture. However, the treatment gap is large because of several barriers, including stigmatisation and drin[...]![]()
Article : Périodique
R. KNIGHT ; P. ROUX ; A. VILOTITCH ; F. MARCELLIN ; E. ROSENTHAL ; L. ESTERLE ; F. BOUE ; D. REY ; L. PIROTH ; S. DOMINGUEZ ; P. SOGNI ; D. SALMON-CERON ; B. SPIRE ; M. P. CARRIERI ; ANRS CO13-HEPAVIH Study Group |Background and aims: Few data exist on changes to substance use patterns before and after hepatitis C virus (HCV) treatment. We used longitudinal data of HIV-HCV co-infected individuals to examine whether receiving pegylated interferon (Peg-IFN)[...]![]()
Article : Périodique
T. BARRE ; F. MARCELLIN ; V. DI BEO ; J. DELORME ; T. ROJAS ROJAS ; P. MATHURIN ; C. PROTOPOPESCU ; F. BAILLY ; M. COSTE ; N. AUTHIER ; M. P. CARRIERI ; B. ROLLAND |BACKGROUND AND AIMS: Although people who inject drugs (PWID) are the core at-risk population in the hepatitis C virus (HCV) epidemic in industrialized countries, few initiate treatment. Alcohol use disorder (AUD), common within this population, [...]